Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation by Shiqi Mao

No abstract

Chin Med J (Engl). 2023 Mar 15. doi: 10.1097/CM9.0000000000002453. Online ahead of print.

NO ABSTRACT

PMID:36921117 | DOI:10.1097/CM9.0000000000002453

Read More